Sotorasib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 564 publications

Clinical characteristics of 20 lung adenocarcinoma patients misdiagnosed as interstitial pneumonia

Clinical characteristics of 20 lung adenocarcinoma patients misdiagnosed as interstitial pneumonia

Journal: Zhonghua yi xue za zhi

Published: March 19, 2026

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.

Journal: Cancer investigation

Published: March 05, 2026

MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy.

MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy.

Journal: International journal of molecular sciences

Published: January 22, 2026

Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.

Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.

Journal: Journal for immunotherapy of cancer

Published: January 20, 2026

Clinically actionable molecular alterations in Rb-retained small cell lung carcinoma variants.

Clinically actionable molecular alterations in Rb-retained small cell lung carcinoma variants.

Journal: Virchows Archiv : an international journal of pathology

Published: January 15, 2026

PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.

PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.

Journal: bioRxiv : the preprint server for biology

Published: January 09, 2026

An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.

An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.

Journal: Expert opinion on investigational drugs

Published: January 08, 2026

Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare payer perspective.

Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare payer perspective.

Journal: Journal of medical economics

Published: January 05, 2026

Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report.

Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report.

Journal: Frontiers in oncology

Published: December 27, 2025

Recent Therapeutic Development Targeting KRAS Mutations in Colorectal Cancer

Recent Therapeutic Development Targeting KRAS Mutations in Colorectal Cancer

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: December 24, 2025

PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer.

PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer.

Journal: bioRxiv : the preprint server for biology

Published: December 22, 2025

Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.

Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2025

Showing 1-12 of 564

Last Updated: 04/28/2026